1 citations
,
April 2008 in “Progrès en Urologie” Finasteride shows promise for preventing prostate cancer, but more research is needed.
38 citations
,
October 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” 5-alpha reductase deficiency leads to male sexual development issues and treatments like finasteride help with prostate enlargement and hair loss.
6 citations
,
June 2009 in “Journal of Clinical Oncology” 5-α-reductase inhibitors don't prevent prostate cancer but may reduce unnecessary biopsies.
21 citations
,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism”
3 citations
,
December 2000 in “Journal of the Royal Society of Medicine” Antiandrogen therapy may be beneficial for women with hidradenitis suppurativa.
January 2011 in “Bloomsbury Academic eBooks” September 2004 in “Urology” Dutasteride may help prevent prostate cancer, but more research is needed.
January 2011 in “Reactions Weekly”
September 2009 in “European Urology Supplements” IGRT resulted in lower acute toxicity for stage III prostate cancer patients.
January 2019 in “Indian Journal of Dermatology, Venereology and Leprology”
August 2009 in “Reactions Weekly” Finasteride caused breast enlargement in two men, which improved after stopping the medication.
8 citations
,
April 2004 in “The Journal of Urology” Doxazosin and finasteride negatively affect sexual function in men with BPH.
Finasteride may cause changes in dopamine-related genes, possibly leading to post-finasteride syndrome.
57 citations
,
January 1986 in “The Prostate” The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
17 citations
,
December 2018 in “The World Journal of Men s Health” Long-term use of dutasteride can cause permanent erectile dysfunction in rats.
January 2013 in “Zhonghua linchuang yishi zazhi” Taking finasteride for over a month before surgery reduces blood loss during TURP.
Combining α-blockers and Finasteride is useful for treating small prostate enlargement.
33 citations
,
January 2009 in “Journal of Cutaneous and Aesthetic Surgery” Finasteride reduces prostate cancer risk but may affect ejaculatory volume and requires careful consideration for young men.
12 citations
,
January 1993 in “PubMed”
January 2018 in “Universidad Privada Antenor Orrego” Male pattern baldness may be an early sign of noncancerous prostate enlargement.
2 citations
,
May 2014 in “BMC Infectious Diseases” HIV-positive men who have sex with men have a higher rate of anal beta-papillomavirus infections.
February 2026 in “The Journal of Sexual Medicine” GnRH agonists can help manage recurrent priapism in sickle cell patients, but long-term safety is unclear.
4 citations
,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
1 citations
,
January 2012 in “Daehan namseong gwahag hoeji” Dutasteride is more effective than Finasteride in reducing prostate size and PSA levels, but both drugs have similar side effects.
November 2023 in “Clinical, Cosmetic and Investigational Dermatology” A man's rash caused by Finasteride improved after stopping the drug and starting new treatments.
March 2005 in “European Urology Supplements”
20 citations
,
August 2018 in “The World Journal of Men's Health” Finasteride may increase erectile dysfunction risk in patients with benign prostatic hyperplasia.
January 2017 in “Clinical pharmacist” Long use of finasteride and dutasteride can cause long-term erection problems.